176 related articles for article (PubMed ID: 25117408)
1. Hepatic portal vein denervation impairs oral glucose tolerance but not exenatide's effect on glycemia.
Ionut V; Castro AV; Woolcott OO; Stefanovski D; Iyer MS; Broussard JL; Burch M; Elazary R; Kolka CM; Mkrtchyan H; Bediako IA; Bergman RN
Am J Physiol Endocrinol Metab; 2014 Oct; 307(8):E644-52. PubMed ID: 25117408
[TBL] [Abstract][Full Text] [Related]
2. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.
Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K
Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371
[TBL] [Abstract][Full Text] [Related]
3. Exenatide can reduce glucose independent of islet hormones or gastric emptying.
Ionut V; Zheng D; Stefanovski D; Bergman RN
Am J Physiol Endocrinol Metab; 2008 Aug; 295(2):E269-77. PubMed ID: 18492781
[TBL] [Abstract][Full Text] [Related]
4. Exenatide Treatment Alone Improves β-Cell Function in a Canine Model of Pre-Diabetes.
Ionut V; Woolcott OO; Mkrtchyan HJ; Stefanovski D; Kabir M; Iyer MS; Liu H; Castro AV; Wu Q; Broussard JL; Kolka CM; Asare-Bediako I; Bergman RN
PLoS One; 2016; 11(7):e0158703. PubMed ID: 27398720
[TBL] [Abstract][Full Text] [Related]
5. Long-term metabolic benefits of exenatide in mice are mediated solely via the known glucagon-like peptide 1 receptor.
Tatarkiewicz K; Sablan EJ; Polizzi CJ; Villescaz C; Parkes DG
Am J Physiol Regul Integr Comp Physiol; 2014 Apr; 306(7):R490-8. PubMed ID: 24477544
[TBL] [Abstract][Full Text] [Related]
6. Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans.
van Raalte DH; van Genugten RE; Linssen MM; Ouwens DM; Diamant M
Diabetes Care; 2011 Feb; 34(2):412-7. PubMed ID: 21216851
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats.
Vahl TP; Tauchi M; Durler TS; Elfers EE; Fernandes TM; Bitner RD; Ellis KS; Woods SC; Seeley RJ; Herman JP; D'Alessio DA
Endocrinology; 2007 Oct; 148(10):4965-73. PubMed ID: 17584962
[TBL] [Abstract][Full Text] [Related]
8. The GLP-1 mimetic exenatide potentiates insulin secretion in healthy cats.
Gilor C; Graves TK; Gilor S; Ridge TK; Rick M
Domest Anim Endocrinol; 2011 Jul; 41(1):42-9. PubMed ID: 21645806
[TBL] [Abstract][Full Text] [Related]
9. Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor.
Burcelin R; Da Costa A; Drucker D; Thorens B
Diabetes; 2001 Aug; 50(8):1720-8. PubMed ID: 11473030
[TBL] [Abstract][Full Text] [Related]
10. Effects of intraportal exenatide on hepatic glucose metabolism in the conscious dog.
Edgerton DS; An Z; Johnson KM; Farmer T; Farmer B; Neal D; Cherrington AD
Am J Physiol Endocrinol Metab; 2013 Jul; 305(1):E132-9. PubMed ID: 23673158
[TBL] [Abstract][Full Text] [Related]
11. Acute metabolic effects of exenatide in patients with type 1 diabetes with and without residual insulin to oral and intravenous glucose challenges.
Ghazi T; Rink L; Sherr JL; Herold KC
Diabetes Care; 2014; 37(1):210-6. PubMed ID: 23939544
[TBL] [Abstract][Full Text] [Related]
12. Exenatide and weight loss.
Bradley DP; Kulstad R; Schoeller DA
Nutrition; 2010 Mar; 26(3):243-9. PubMed ID: 20152707
[TBL] [Abstract][Full Text] [Related]
13. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia.
Degn KB; Brock B; Juhl CB; Djurhuus CB; Grubert J; Kim D; Han J; Taylor K; Fineman M; Schmitz O
Diabetes; 2004 Sep; 53(9):2397-403. PubMed ID: 15331551
[TBL] [Abstract][Full Text] [Related]
14. The GLP-1 analogue exenatide improves hepatic and muscle insulin sensitivity in diabetic rats: tracer studies in the basal state and during hyperinsulinemic-euglycemic clamp.
Wu H; Sui C; Xu H; Xia F; Zhai H; Zhang H; Weng P; Han B; Du S; Lu Y
J Diabetes Res; 2014; 2014():524517. PubMed ID: 25580440
[TBL] [Abstract][Full Text] [Related]
15. Effects of exendin-4 on glucose tolerance, insulin secretion, and beta-cell proliferation depend on treatment dose, treatment duration and meal contents.
Arakawa M; Ebato C; Mita T; Hirose T; Kawamori R; Fujitani Y; Watada H
Biochem Biophys Res Commun; 2009 Dec; 390(3):809-14. PubMed ID: 19836346
[TBL] [Abstract][Full Text] [Related]
16. Effects of prolonged exendin-4 administration on entero-insular axis of normal and streptozotocin-induced diabetic rats.
Malendowicz LK; Macchi C; Nussdorfer GG; Nowak KW; Zyterska A; Ziolkowska A
Int J Mol Med; 2003 Jun; 11(6):763-6. PubMed ID: 12736719
[TBL] [Abstract][Full Text] [Related]
17. Essentiality of portal vein receptors in hypoglycemic counterregulation: direct proof via denervation in male canines.
Ionut V; Castro AV; Woolcott OO; Stefanovski D; Iyer MS; Broussard JL; Mkrtchyan H; Burch M; Elazary R; Kirkman E; Bergman RN
Endocrinology; 2014 Apr; 155(4):1247-54. PubMed ID: 24428530
[TBL] [Abstract][Full Text] [Related]
18. Pharmacology of the glucagon-like peptide-1 analog exenatide extended-release in healthy cats.
Rudinsky AJ; Adin CA; Borin-Crivellenti S; Rajala-Schultz P; Hall MJ; Gilor C
Domest Anim Endocrinol; 2015 Apr; 51():78-85. PubMed ID: 25594949
[TBL] [Abstract][Full Text] [Related]
19. Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes.
Ghofaili KA; Fung M; Ao Z; Meloche M; Shapiro RJ; Warnock GL; Elahi D; Meneilly GS; Thompson DM
Transplantation; 2007 Jan; 83(1):24-8. PubMed ID: 17220786
[TBL] [Abstract][Full Text] [Related]
20. GLP-1, exendin-4 and C-peptide regulate pancreatic islet microcirculation, insulin secretion and glucose tolerance in rats.
Wu L; Olverling A; Huang Z; Jansson L; Chao H; Gao X; Sjöholm Å
Clin Sci (Lond); 2012 Apr; 122(8):375-84. PubMed ID: 22054347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
